• Recombinant Mouse SHH: Bridging Morphogen Biology and Assay

  2026-08-06

  Explore the essential role of Recombinant Mouse Sonic Hedgehog (SHH) in developmental biology and congenital malformation research. This article reveals new insights into SHH’s assay precision, species-specific morphogenesis, and practical protocols, providing a distinct perspective beyond standard applications.

• Proteasome Inhibition: Strategic Leverage in Translational R

  2026-08-06

  This thought-leadership article explores how reversible proteasome inhibitors such as Bortezomib (PS-341) are redefining translational research in oncology and regenerative immunology. Integrating mechanistic insights from recent studies, we outline practical protocols, address evolving paradigms in apoptosis and immune recovery, and provide strategic guidance for researchers seeking to bridge preclinical advances with transformative clinical applications. By situating Bortezomib within the broader scientific and therapeutic landscape, we highlight actionable opportunities and emerging frontiers for translational teams.

• Verbascoside: Applied PKC/NF-κB Inhibitor for Osteoclastogen

  2026-08-05

  Verbascoside stands out as a precision PKC/NF-κB inhibitor for dissecting osteoclastogenesis and inflammatory signaling, enabling reliable and reproducible pathway modulation in bone metabolism studies. This article provides actionable workflows, troubleshooting strategies, and highlights from the latest mechanistic research to maximize experimental impact.

• Cy3 Rabbit Anti-Goat IgG (H+L) Antibody: Technical Use Guide

  2026-08-05

  The Cy3 Rabbit Anti-Goat IgG (H+L) Antibody provides specific, sensitive detection of goat IgG in fluorescence-based immunodetection workflows using a Cy3-conjugated secondary format. This reagent should be used exclusively with goat primary antibodies in validated applications such as ICC/IF, IHC, flow cytometry, and ELISA. It is not appropriate for detecting non-goat primaries or for non-immunodetection purposes.

• Transmission Dynamics of Carbapenemase Genes in CREC: Guangd

  2026-08-04

  This study provides the first multi-hospital molecular characterization of carbapenemase-encoding genes (CEGs) in carbapenem-resistant Enterobacter cloacae (CREC) during the COVID-19 pandemic in Guangdong. Key findings emphasize the prevalence of plasmid-mediated blaNDM-1, high multidrug resistance rates, and efficient horizontal gene transfer, offering critical insights for antibiotic resistance surveillance and research.

• Liproxstatin-1 HCl: Applied Ferroptosis Inhibition Workflows

  2026-08-04

  Liproxstatin-1 HCl delivers nanomolar-selective ferroptosis inhibition, enabling high-fidelity research in acute renal failure and hepatic ischemia/reperfusion injury. This article translates cutting-edge mitochondrial calcium signaling insights into optimized workflows, troubleshooting, and protocol enhancements for reproducible ferroptosis assays.

• EdU Imaging Kits: Precision Cell Proliferation Assays Unlock

  2026-08-03

  EdU Imaging Kits (HF488) empower researchers to quantify cell proliferation with unmatched sensitivity and workflow simplicity, leveraging click chemistry for high-fidelity DNA synthesis measurement. Optimized for both fluorescence microscopy and flow cytometry, these kits bypass the pitfalls of traditional BrdU assays, accelerating discovery in oncology and drug development.

• CA-074 Me: Precision Cathepsin B Inhibitor for Lysosomal Ass

  2026-08-03

  CA-074 Me enables highly selective, membrane-permeable inhibition of cathepsin B, empowering researchers to unravel lysosomal cell death pathways and optimize apoptosis assays. Its robust performance in both cellular and in vivo models sets a new standard for reproducibility and specificity in inflammation and necroptosis research.

• Chenodeoxycholic Acid in FXR Signaling and Renal Protection

  2026-08-02

  Chenodeoxycholic Acid (CDCA) is redefining FXR-based research in cholesterol metabolism and kidney injury models, offering robust, reproducible modulation of nuclear receptor pathways. This guide delivers proven experimental workflows, troubleshooting strategies, and translational insights for maximizing scientific outcomes with CDCA from APExBIO.

• Aurora Kinase A Overexpression in Retinoblastoma: Study Insi

  2026-08-01

  This study provides compelling evidence that Aurora kinase A (AURKA) is significantly overexpressed in human retinoblastoma and closely associates with histopathologic high-risk features and chemotherapy resistance. These findings support the rationale for targeted AURKA inhibition as a promising strategy in high-risk or refractory retinoblastoma cases.

• Rhodamine 123 (chloride): Advancing P-glycoprotein Efflux As

  2026-07-31

  Rhodamine 123 (chloride) is a gold-standard fluorescent substrate for dissecting membrane transporter function, with unique dual uptake pathways and real-time assay sensitivity that set it apart from other dyes. Recent breakthroughs in ABC transporter modulation further empower its use for multidrug resistance research and oncology workflows.

• WST-8 Glucose Uptake Assay Kit: Protocol Innovation & Optimi

  2026-07-31

  The WST-8 Glucose Uptake Assay Kit enables rapid, non-radioactive quantification of cellular glucose uptake, empowering researchers in metabolic, diabetes, and cancer biology. Discover advanced workflow enhancements, real-world troubleshooting, and the critical impact of ionic supplementation on assay sensitivity and reliability.

• Annular Sector Microneedle Enables Targeted Gene Therapy for

  2026-07-30

  The reference study introduces a novel annular sector-shaped microneedle patch enabling localized, combinatorial delivery of Nmnat1 gene nanoparticles and nicotinamide to the trabecular meshwork in glaucoma models. This approach reverses mitochondrial dysfunction, lowers intraocular pressure, and highlights the translational potential of advanced gene delivery strategies in ocular disease.

• WY-14643 (Pirinixic Acid): New Horizons in PPARα-Targeted Me

  2026-07-30

  This thought-leadership article explores the mechanistic and translational value of WY-14643 (Pirinixic Acid) as a selective PPARα agonist, highlighting its unique role in metabolic disorder research, inflammation control, and emerging insights into hepatoprotection. Drawing on recent advances and referencing a landmark study on PPARα-mediated pyroptosis inhibition, the piece delivers actionable guidance for translational scientists navigating the evolving landscape of metabolic and liver disease modeling.

• Thiamet G and O-GlcNAcase Inhibition: Precision Tools for Pr

  2026-07-29

  Explore how Thiamet G, a leading O-GlcNAcase inhibitor, enables targeted modulation of cellular O-GlcNAc levels, unlocking new experimental strategies in metabolism and disease research. This article uniquely integrates recent findings on O-GlcNAcylation’s metabolic control, providing actionable insights for advanced assay design.

16058 records 1/1071 page Next 12345 下5页 Last page